BG103521A - Substituted pyrimidinon and pyridon compounds and methods for their application - Google Patents
Substituted pyrimidinon and pyridon compounds and methods for their applicationInfo
- Publication number
- BG103521A BG103521A BG103521A BG10352199A BG103521A BG 103521 A BG103521 A BG 103521A BG 103521 A BG103521 A BG 103521A BG 10352199 A BG10352199 A BG 10352199A BG 103521 A BG103521 A BG 103521A
- Authority
- BG
- Bulgaria
- Prior art keywords
- compounds
- methods
- pyridon
- substituted
- pyrimidinon
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The new substituted pyrimidon and pyridon compounds are effective for the prevention and treatment of diseases running with the mediation of TNF-alpha,IL-1beta, IL-6 and/or IL-6, and/or IL-8, as well as for easying of pains and in diabetes. The invention relates to new compounds, to their analogues, promedicamentous forms and their pharmaceutically acceptable salts, to pharmaceutical compositions and methods for the prevention and treatment of diseases and other sufferings or conditions occurring with inflammations, pains, diabetes, and others. The invention also relates to methods for the preparation of the compounds and to intermediate products for their preparation. 46 claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3212896P | 1996-12-05 | 1996-12-05 | |
US5095097P | 1997-06-13 | 1997-06-13 | |
US97605397A | 1997-11-21 | 1997-11-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
BG103521A true BG103521A (en) | 2000-07-31 |
BG65129B1 BG65129B1 (en) | 2007-03-30 |
Family
ID=27364029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG103521A BG65129B1 (en) | 1996-12-05 | 1999-06-23 | Substituted pyrimidinon and pyridon compounds and methods of application |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0948496A2 (en) |
JP (1) | JP2002514196A (en) |
KR (1) | KR100476586B1 (en) |
CN (1) | CN1328277C (en) |
AU (1) | AU735901C (en) |
BG (1) | BG65129B1 (en) |
BR (1) | BR9713863A (en) |
CA (1) | CA2274093C (en) |
CZ (1) | CZ9902016A3 (en) |
HU (1) | HUP0001140A3 (en) |
IL (1) | IL130181A0 (en) |
NZ (1) | NZ335992A (en) |
WO (1) | WO1998024780A2 (en) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6410729B1 (en) * | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
EP1037639A4 (en) | 1997-12-19 | 2002-04-17 | Smithkline Beecham Corp | Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses |
US6858617B2 (en) | 1998-05-26 | 2005-02-22 | Smithkline Beecham Corporation | Substituted imidazole compounds |
TWI241298B (en) * | 1998-09-25 | 2005-10-11 | Mitsubishi Chem Corp | Pyrimidone derivatives |
JP2002528506A (en) | 1998-11-04 | 2002-09-03 | スミスクライン・ビーチャム・コーポレイション | Pyridin-4-yl or pyrimidin-4-yl substituted pyrazine |
GB9910378D0 (en) * | 1999-05-05 | 1999-06-30 | Smithkline Beecham Plc | Novel compounds |
US6503949B1 (en) | 1999-05-17 | 2003-01-07 | Noro Nordisk A/S | Glucagon antagonists/inverse agonists |
US6403596B1 (en) | 1999-06-28 | 2002-06-11 | Merck & Co., Inc. | Substituted pyridones having cytokine inhibitory activity |
EP1233951B1 (en) | 1999-11-23 | 2005-06-01 | SmithKline Beecham Corporation | 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors |
US6982270B1 (en) | 1999-11-23 | 2006-01-03 | Smithkline Beecham Corporation | 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors |
US6759410B1 (en) | 1999-11-23 | 2004-07-06 | Smithline Beecham Corporation | 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors |
EP1136099A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Indolylalkylamino)pyrimidone derivatives as GSK3beta inhibitors |
EP1136482A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
EP1136493A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-(Thienopyridinyl)pyrimidone, 2-(furopyridinyl)pyrimidone 2-(isoquinolinyl)pyrimidone, 2-(pyridoindolyl)pyrimidone and 2-(benzofuropyridinyl)pyrimidone derivatives |
JP2005289808A (en) * | 2000-03-23 | 2005-10-20 | Sanofi-Aventis | 3-substituted-4-pyrimidone derivative |
NZ521633A (en) | 2000-04-26 | 2005-01-28 | Eisai Co Ltd | Use of an adenosine A2 or A2b recpetor antagonist for promoting bowel movement |
PT1300396E (en) | 2000-06-12 | 2009-04-20 | Eisai R&D Man Co Ltd | 1,2-dihydropyridine compounds, process for preparation of the same and use thereof |
US7115608B2 (en) * | 2000-09-19 | 2006-10-03 | Centre National De La Recherche Schentifique | Pyridinone and pyridinethione derivatives having HIV inhibiting properties |
GB0024808D0 (en) * | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
US6821960B2 (en) | 2000-11-17 | 2004-11-23 | Noyo Nordisk Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
AU2002223500A1 (en) | 2000-11-17 | 2002-05-27 | Novo-Nordisk A/S | Glucagon antagonists/inverse agonists |
US6706744B2 (en) | 2000-11-17 | 2004-03-16 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
DK1427709T3 (en) | 2001-09-21 | 2006-04-03 | Mitsubishi Pharma Corp | 3-substituted 4-pyrimidone derivatives |
DK1430057T3 (en) * | 2001-09-21 | 2006-01-16 | Sanofi Aventis | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo [1,2-a] pyrimidine-5 (1H) one derivatives |
EP1295884A1 (en) * | 2001-09-21 | 2003-03-26 | Sanofi-Synthelabo | 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 7-Pyrimidinyl-2,3-Dihydroimidazo[1,2-a]Pyrimidin-5(1H)one derivatives |
EP1295885A1 (en) * | 2001-09-21 | 2003-03-26 | Sanofi-Synthelabo | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives |
EA009456B1 (en) * | 2001-09-21 | 2007-12-28 | Санофи-Авентис | PYRIMIDONE DERIVATIVES AS INTERMEDIATES FOR PREPARING GSK3β OR GSK3β AND cdk5/p25 INHIBITORS |
TWI330183B (en) * | 2001-10-22 | 2010-09-11 | Eisai R&D Man Co Ltd | |
TWI301834B (en) * | 2001-10-22 | 2008-10-11 | Eisai R&D Man Co Ltd | Pyrimidone compound and pharmaceutical composition including the same |
US6921762B2 (en) | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
US6762318B2 (en) | 2001-12-03 | 2004-07-13 | Novo Nordisk A/S | Glucagon antagonists |
US6881746B2 (en) | 2001-12-03 | 2005-04-19 | Novo Nordick A/S | Glucagon antagonists/inverse agonists |
EP1458717B1 (en) * | 2001-12-21 | 2005-09-07 | Bayer HealthCare AG | Aroyl pyridinones |
AU2003216585A1 (en) * | 2002-04-10 | 2003-10-20 | Orchid Chemicals And Pharmaceuticals Limited | Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases |
WO2003099808A1 (en) * | 2002-05-21 | 2003-12-04 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
WO2004004725A2 (en) | 2002-07-09 | 2004-01-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases |
CN1726209B (en) | 2002-12-16 | 2011-04-13 | 三菱制药株式会社 | 3-substituted-4-pyrimidone derivatives |
TWI357408B (en) | 2003-03-26 | 2012-02-01 | Mitsubishi Tanabe Pharma Corp | 3-substituted-4-pyrimidone derivatives |
US7183287B2 (en) * | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
US20070167621A1 (en) | 2003-04-03 | 2007-07-19 | Pharmacia Corporation | Substituted pyrimidinones |
US7049318B2 (en) * | 2003-07-25 | 2006-05-23 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
EP1506967B1 (en) * | 2003-08-13 | 2007-11-21 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7429594B2 (en) | 2003-08-20 | 2008-09-30 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
SE0302486D0 (en) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
EP1557417B1 (en) * | 2003-12-19 | 2007-03-07 | Sanofi-Aventis | Substituted 8'-pyri(mi)dinyl-dihydrospiro-[cycloalkylamine]-pyrimido[1,2-a] pyrimidin-6-one derivatives |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
EP2708531A1 (en) | 2004-10-13 | 2014-03-19 | Pharmacia & Upjohn Company LLC | Crystalline Forms Of 3-[5-Chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide |
EP1831168B1 (en) | 2004-12-16 | 2014-07-02 | Vertex Pharmaceuticals Inc. | Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases. |
PE20060777A1 (en) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES |
MY147393A (en) | 2005-09-14 | 2012-11-30 | Takeda Pharmaceutical | Administration of dipeptidyl peptidase inhibitors |
CN102675221A (en) | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | Intermediate in method for preparing pyrimidinedione derivative |
AR059898A1 (en) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | DERIVATIVES OF 3-CIANO-PIRIDONA 1,4-DISUSTITUTED AND ITS USE AS ALLOSTERIC MODULATORS OF MGLUR2 RECEIVERS |
TW200808771A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
TW200808763A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
WO2008104752A1 (en) * | 2007-02-26 | 2008-09-04 | Astrazeneca Ab | Dihydropyridones as elastase inhibitors |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
NZ584152A (en) | 2007-09-14 | 2011-11-25 | Ortho Mcneil Janssen Pharm | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
PT2203439E (en) | 2007-09-14 | 2011-02-11 | Ortho Mcneil Janssen Pharm | 1`,3`-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1`h-ý1, 4`¨bipyridinyl-2`-ones |
US8466284B2 (en) | 2007-11-06 | 2013-06-18 | Astra Zeneca Ab | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
BRPI0918055A2 (en) | 2008-09-02 | 2015-12-01 | Addex Pharmaceuticals Sa | 3-azabicyclo [3,1,0] hexyl derivatives as metabotropic glutamate receptor modulators. |
US8598209B2 (en) * | 2008-10-31 | 2013-12-03 | Merck Sharp & Dohme Corp. | P2X3, receptor antagonists for treatment of pain |
JP5690277B2 (en) | 2008-11-28 | 2015-03-25 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
CN102439015B (en) | 2009-05-12 | 2015-05-13 | 杨森制药有限公司 | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
NZ596078A (en) | 2009-05-12 | 2013-06-28 | Janssen Pharmaceuticals Inc | 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
CN102639505A (en) | 2009-10-02 | 2012-08-15 | 阿斯利康(瑞典)有限公司 | 2-pyridone compounds used as inhibitors of neutrophil elastase |
US9271967B2 (en) | 2010-11-08 | 2016-03-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
CA2814998C (en) | 2010-11-08 | 2019-10-29 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
US8993591B2 (en) | 2010-11-08 | 2015-03-31 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
MX2013006768A (en) | 2010-12-23 | 2013-07-22 | Pfizer | Glucagon receptor modulators. |
EA023517B1 (en) | 2011-02-08 | 2016-06-30 | Пфайзер Инк. | Glucagon receptor modulators |
CN103635472B (en) | 2011-02-28 | 2018-01-12 | 阵列生物制药公司 | Serine/threonine kinase inhibitor |
US8927577B2 (en) | 2011-07-22 | 2015-01-06 | Pfizer Inc. | Quinolinyl glucagon receptor modulators |
CN103958502B (en) | 2011-08-04 | 2016-02-10 | 阵列生物制药公司 | As the quinazoline compound of serine/threonine kinase inhibitor |
GEP201706656B (en) | 2011-11-11 | 2017-04-25 | Pfizer | 2-thiopyrimidinones |
CN103130787B (en) * | 2011-11-24 | 2015-06-10 | 南开大学 | Pyrimidone amide compound, and preparation method, anti-HIV activity and anti-TMV activity thereof |
CA2866086C (en) | 2012-03-01 | 2020-06-09 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
CN105143200B (en) | 2012-08-27 | 2018-10-16 | 阵列生物制药公司 | Serine/threonine kinase inhibitor for treating excess proliferative disease |
JO3368B1 (en) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
JO3367B1 (en) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
ME03518B (en) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
SI3096790T1 (en) | 2014-01-21 | 2019-11-29 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
KR101693781B1 (en) * | 2014-10-06 | 2017-01-09 | 한양대학교 에리카산학협력단 | Method for producing difluoroalkylated amromatics |
WO2016178113A1 (en) | 2015-05-05 | 2016-11-10 | Pfizer Inc. | 2-thiopyrimidinones |
CN107200731B (en) * | 2017-06-11 | 2020-10-23 | 湖南科技大学 | Thiazole ring-containing pyridone derivative and preparation method and application thereof |
CN110078674B (en) * | 2019-04-10 | 2022-11-01 | 昆明理工大学 | Preparation method of 2-alkyl amino pyrimidone |
KR102598203B1 (en) | 2019-11-25 | 2023-11-03 | 암젠 인크 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use |
CN115650906A (en) * | 2022-11-04 | 2023-01-31 | 苏州艾缇克药物化学有限公司 | Preparation method of 2-aminoisonicotinic acid |
WO2024119067A1 (en) | 2022-12-02 | 2024-06-06 | Neumora Therapeutics, Inc. | Methods of treating neurological disorders |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1271116B (en) * | 1965-05-04 | 1968-06-27 | Bayer Ag | Process for the preparation of 4-hydroxypyrimidines |
JPS6163680A (en) * | 1984-09-05 | 1986-04-01 | Kanto Ishi Pharma Co Ltd | Pyrimido(1,2-a)benzimidazole derivative and its preparation |
US5620999A (en) * | 1994-07-28 | 1997-04-15 | Weier; Richard M. | Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation |
WO1997012876A1 (en) * | 1995-10-06 | 1997-04-10 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
AU702887B2 (en) * | 1995-10-31 | 1999-03-11 | Merck & Co., Inc. | Substituted pyridyl pyrroles, compositions containing such compounds and methods of use |
-
1997
- 1997-12-04 WO PCT/US1997/022949 patent/WO1998024780A2/en not_active Application Discontinuation
- 1997-12-04 CZ CZ992016A patent/CZ9902016A3/en unknown
- 1997-12-04 BR BR9713863-0A patent/BR9713863A/en not_active Application Discontinuation
- 1997-12-04 CN CNB971815585A patent/CN1328277C/en not_active Expired - Fee Related
- 1997-12-04 AU AU55254/98A patent/AU735901C/en not_active Ceased
- 1997-12-04 NZ NZ335992A patent/NZ335992A/en unknown
- 1997-12-04 KR KR10-1999-7005022A patent/KR100476586B1/en not_active IP Right Cessation
- 1997-12-04 CA CA002274093A patent/CA2274093C/en not_active Expired - Fee Related
- 1997-12-04 EP EP97951678A patent/EP0948496A2/en not_active Withdrawn
- 1997-12-04 IL IL13018197A patent/IL130181A0/en unknown
- 1997-12-04 HU HU0001140A patent/HUP0001140A3/en unknown
- 1997-12-04 JP JP52590298A patent/JP2002514196A/en active Pending
-
1999
- 1999-06-23 BG BG103521A patent/BG65129B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU5525498A (en) | 1998-06-29 |
CN1328277C (en) | 2007-07-25 |
KR100476586B1 (en) | 2005-03-18 |
IL130181A0 (en) | 2000-06-01 |
BR9713863A (en) | 2000-03-14 |
WO1998024780A2 (en) | 1998-06-11 |
AU735901C (en) | 2004-02-12 |
BG65129B1 (en) | 2007-03-30 |
WO1998024780A3 (en) | 1998-07-30 |
CN1246857A (en) | 2000-03-08 |
HUP0001140A3 (en) | 2002-05-28 |
HUP0001140A2 (en) | 2001-04-28 |
CZ9902016A3 (en) | 1999-11-17 |
CA2274093C (en) | 2006-11-07 |
CA2274093A1 (en) | 1998-06-11 |
EP0948496A2 (en) | 1999-10-13 |
KR20000069329A (en) | 2000-11-25 |
AU735901B2 (en) | 2001-07-19 |
JP2002514196A (en) | 2002-05-14 |
NZ335992A (en) | 2001-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG103521A (en) | Substituted pyrimidinon and pyridon compounds and methods for their application | |
IL136711A0 (en) | Substituted pyridine and pyridazine compounds and their pharmaceutical use | |
PL371428A1 (en) | Substituted indolizine-like compounds and methods of use | |
ES2177780T3 (en) | MEDICATIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES USING INTERFERON TAU. | |
WO1998024782A3 (en) | Substituted pyrimidine compounds and their use | |
MY137348A (en) | Highly selective norepinephrine reuptake inhibitors and methods of using the same | |
CA2427227A1 (en) | Lactam compound | |
ATE167057T1 (en) | SUBLINGUAL OR BUCCAL MEDICINAL PRODUCT | |
WO1997049373A3 (en) | Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin | |
ES2177642T3 (en) | USE OF CERTAIN DERIVATIVES OF METHANOPHYPHOSPHONIC ACID TO PREVENT DETACHMENT AND MIGRATION OF PROTESIS. | |
MXPA05003302A (en) | Therapeutic piperazine compounds. | |
CA2198706A1 (en) | Methods for the treatment of inflammatory joint disease | |
ES2160643T3 (en) | COMPOSITIONS CONTAINING G-CSF AND PROTEIN OF UNION TO TNF. | |
BG103512A (en) | Substituted pyramidine compounds and their application | |
ES2187646T3 (en) | PROCEDURES FOR THE TREATMENT OF INFLAMMATIONS AND CORRESPONDING COMPOSITIONS. | |
BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
WO2004043373A3 (en) | Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme | |
WO1999045909A3 (en) | Use of nitrone compounds for the inhibition of angiogenesis | |
AU2173101A (en) | Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents | |
HUP9903679A2 (en) | Use of olanzapine for the preparation of pharmaceutical compositions treating bipolar disorder | |
ATE184489T1 (en) | TREATMENT OF LACK OF MILK SECTION IN HUMAN BEINGS | |
UA41326C2 (en) | Pharmaceutical composition for prevention or treatment of viral diseases, means for prevention or treatment of viral diseases | |
EA199800941A1 (en) | THERAPEUTICALLY MEANS CONTAINING OXYGEN ANION-RADICALS AND / OR PRODUCTS OF THEIR SUBSEQUENTAL TURNING AND DIVISION AND THEIR APPLICATION FOR THE TREATMENT OF PARKINSON'S DISEASE | |
MX9500324A (en) | Pharmaceutical compounds and the use of the same in the treatment of neurological diseases and their related symptomatic ethiologies. | |
EP1314732A3 (en) | Substituted pyrimidine compounds and their use |